Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ATACAND

« Back to Dashboard
Atacand is a drug marketed by Astrazeneca and is included in two NDAs. It is available from eight suppliers. There is one patent protecting this drug and three Paragraph IV challenges.

The generic ingredient in ATACAND is candesartan cilexetil; hydrochlorothiazide. There are twenty-one drug master file entries for this compound. Four suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.

Summary for Tradename: ATACAND

Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: see list28

Pharmacology for Tradename: ATACAND

Clinical Trials for: ATACAND

CKD-330 Drug-Drug Interaction Study (Candesartan)
Status: Completed Condition: Hypertension

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
Status: Completed Condition: Hypertension

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions
Status: Completed Condition: Respiratory Disorders

ARIA (Atacand Renoprotection In NephropAthy Pt.)
Status: Completed Condition: Non-diabetic Nephropathy With Hypertension

Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal
Status: Completed Condition: Healthy

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
Status: Completed Condition: Hypertension

Candesartan Effect in Second Stage Arterial Hypertension
Status: Completed Condition: Stage II Hypertension

Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate
Status: Active, not recruiting Condition: Healthy

Atacand (Candesartan) Real Life Study
Status: Completed Condition: Hypertension

DIabetic Retinopathy Candesartan Trials.
Status: Completed Condition: Type 1 Diabetes

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-001Jun 4, 1998RXNo<disabled><disabled>
Astrazeneca
ATACAND HCT
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL021093-003May 16, 2008RXYes5,721,263<disabled>Y <disabled>
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-004Jun 4, 1998RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ATACAND

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-003Jun 4, 19985,705,517*PED<disabled>
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-004Jun 4, 19985,705,517*PED<disabled>
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-004Jun 4, 19985,703,110<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ATACAND

Drugname Dosage Strength RLD Submissiondate
candesartan cilexetil and hydrochlorothiazideTablets32 mg/25 mgAtacand HCT3/6/2009
candesartan cilexetil and hydrochlorothiazideTablets16 mg/12.5 mg and 32 mg/12.5 mgAtacand HCT6/25/2008
candesartan cilexetilTablets4 mg, 8 mg, 16 mg and 32 mgAtacand12/22/2006
« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc